Organic compounds -- part of the class 532-570 series – Organic compounds – Four or more ring nitrogens in the bicyclo ring system
Reexamination Certificate
2011-04-12
2011-04-12
Balasubramanian, Venkataraman (Department: 1624)
Organic compounds -- part of the class 532-570 series
Organic compounds
Four or more ring nitrogens in the bicyclo ring system
C514S242000
Reexamination Certificate
active
07923554
ABSTRACT:
The present invention relates to HIV replication inhibitors of formulaa N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine or a stereochemically isomeric form thereof, wherein ring A and ring B represent phenyl, pyridyl, pyridazinyl, pyrimidinyl or pyrazinyl; n and m are 1 to 4; R1represents hydrogen; aryl; formyl; C1-6alkylcarbonyl; C1-6alkyloxycarbonyl; optionally substituted C1-6alkyl; C1-6alkyloxyC1-6alkylcarbonyl substituted with C1-6alkyloxycarbonyl; R2or R4represents hydrogen; hydroxy; halo; optionally substituted C1-6alkyl; optionally substituted C2-6alkenyl; optionally substituted C2-6alkynyl; C3-7cycloalkyl; C1-6alkyloxy; C1-6alkyloxycarbonyl; C1-6alkylcarbonyloxy; carboxyl; cyano; nitro; amino; mono- or di(C1-6alkyl)amino; polyhaloC1-4alkyl; polyhaloC1-4alkyloxy; polyhaloC1-4alkylthio; —S(═O)pR6; —NH—S(═O)pR6; —C(═O)R6; —NHC(═O)H; —C(═O)NHNH2; NHC(═O)R6; C(═NH)R6; or R7; R2aor R3represents cyano; aminocarbonyl; amino; halo; NHR13; NR13R14; —C(═O)—NHR13; —C(═O)—NR13R14; —C(═O)—R15; —CH═N—NH—C(═O)—R16; optionally substituted C1-6alkyl; optionally substituted C1-6alkyloxy; optionally substituted C1-6alkyloxyC1-6alkyl; optionally substituted C2-6alkenyl; optionally substituted C2-6alkynyl; —C(═N—O—R8)—C1-4alkyl; R7or —X3—R7; X1or X2represents —NR1—; —NH—NH—; —N═N—; —O—; —C(═O)—; —C1-4alkanediyl-; —CHOH—; —S—; —S(═O)p—; —X4—C1-4alkanediyl-; —C1-4alkanediyl-X4—; or —C1-4alkanediyl-X4—C1-4alkanediyl-; their use as a medicine, their use for the manufacture of a medicament for the treatment or the prevention of HIV infection; their processes for preparation and pharmaceutical compositions comprising them.
REFERENCES:
patent: 3459731 (1969-08-01), Gramera et al.
patent: 2010/0160310 (2010-06-01), Freyne et al.
patent: 0 834 507 (1998-04-01), None
patent: 0834507 (2004-05-01), None
patent: WO 97/18839 (1997-05-01), None
patent: WO 99/50250 (1999-10-01), None
patent: WO 99/50256 (1999-10-01), None
patent: WO 00/27825 (2000-05-01), None
patent: WO 00/27828 (2000-05-01), None
patent: WO 01/85700 (2001-11-01), None
patent: WO 02/078708 (2002-10-01), None
patent: WO 03/016306 (2003-02-01), None
Magden et al., Appl Microbiol Biotechnol (2005) 66: 612-621.
International Search Report dated Nov. 16, 2005 for related International Application No. PCT/EP2005/053936.
Koyanagi, et al., “Selective Cytotoxicity of Aids Virus Infection Towards HTLV-I-Transformed Cell Lines”, Int. J. Cancer, (1985), pp. 445-451, vol. 36(4), Alan R. Liss, Inc.
In the U.S. Patent and Trademark Office, Non-Final Office Action in re: U.S. Appl. No. 11/720,681 dated Sep. 14, 2010, 7 pages.
Arts, legal representative Frank Xavier Jozef Herwig
Daeyaert Frederik Frans Desire
de Jonge Marc René
Heeres Jan
Hoornaert Georges Joseph Cornelius
Balasubramanian Venkataraman
Janssen Pharmaceutica N.V.
Patton & Boggs LLP
LandOfFree
HIV inhibiting 1,2,4-triazin-6-one derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with HIV inhibiting 1,2,4-triazin-6-one derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and HIV inhibiting 1,2,4-triazin-6-one derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2631151